The T-cell-dependent antibody response (TDAR) is a gold standard assay for assessing the impact of drug candidates on immune competence during preclinical development. This functional immune assay evaluates the integrity of multiple immune processes, including antigen uptake and presentation, T cell help, B cell activation, and antibody production. Regulatory agencies recommend TDAR as a first-choice immune function test for immunotoxicity evaluation of new chemical entities. HKeyBio offers a well-validated NHP TDAR model using keyhole limpet hemocyanin (KLH), a highly immunogenic protein that elicits robust T-cell-dependent antibody responses. This model provides critical immunotoxicity and immunopharmacology data to support IND-enabling studies.

Urticaria (hives) is a common mast cell-driven disease characterized by wheal-and-flare reactions, erythema, and intense pruritus. It is classified as acute (≤6 weeks) or chronic (>6 weeks), and can be spontaneous or inducible by specific triggers (cold, pressure, allergens). HKeyBio offers two well-validated NHP urticaria models: (1) HDM induced urticaria model, established by epicutaneous or intradermal sensitization with house dust mite extract, recapitulating allergen-induced acute skin reactions; and (2) DNP-IgE & DNFB induced passive cutaneous anaphylaxis (PCA) model, a classical type I hypersensitivity model mediated by allergen-specific IgE and mast cell degranulation. Both models provide robust platforms for preclinical efficacy testing of novel anti-allergic and mast cell-stabilizing therapeutics.

Psoriasis is a chronic autoimmune skin disease characterized by rapid turnover of skin cells, resulting in dry, scaly, itchy patches (plaques) most commonly on knees, elbows, trunk, and scalp. Plaque psoriasis, the most common type, involves immune system dysfunction leading to hyperproliferation of keratinocytes. HKeyBio offers a well-validated NHP psoriasis model induced by imiquimod (IMQ), a TLR7/8 agonist that triggers psoriasis-like skin inflammation through type I interferon and IL-23/IL-17 pathways. This model recapitulates key human psoriasis features including erythema, scaling, thickening, elevated IL-17A and IL-36, and characteristic histopathological changes, providing a robust platform for preclinical efficacy testing of novel psoriasis therapeutics.

Systemic sclerosis (SSc), also known as scleroderma, is a chronic autoimmune disease characterized by excessive collagen production and accumulation in skin and connective tissues, leading to hardening and tightening. The pathogenesis involves abnormal immune reactions, genetic factors, and environmental triggers. HKeyBio offers a well-validated NHP SSc model induced by intradermal administration of bleomycin (BLM), a chemotherapeutic agent that triggers skin fibrosis closely resembling human SSc. This model recapitulates key features including dermal thickening, collagen deposition, and autoantibody production, providing a robust platform for preclinical efficacy testing of novel anti-fibrotic and immunomodulatory therapeutics.

Sjögren's syndrome (SjS) is a chronic autoimmune disorder characterized by lymphocytic infiltration of exocrine glands, leading to dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia). It often coexists with other autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. HKeyBio offers a well-validated NHP SjS model induced by immunization with salivary gland protein, which recapitulates key human SjS features: reduced salivary flow rate, elevated autoantibodies against salivary gland antigens, and lymphocytic infiltration of salivary glands. This model provides a robust platform for preclinical efficacy testing of novel therapeutics for Sjögren's syndrome.

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by inflammatory polyarthritis, leading to cartilage and bone destruction. HKeyBio offers a well-validated NHP collagen induced arthritis (CIA) model, established by immunization with type II collagen (CII). This model recapitulates key clinical and histological features of human RA, including joint swelling, elevated anti-collagen IgG, and increased acute phase proteins (CRP, ALP). It provides a robust platform for preclinical efficacy testing of novel RA therapeutics.

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract, primarily comprising ulcerative colitis (UC) and Crohn's disease (CD). Characterized by relapsing inflammation, mucosal ulcers, and tissue damage, IBD significantly impacts patients' quality of life. HKeyBio offers a well-validated NHP IBD model induced by dextran sulfate sodium (DSS), which recapitulates key features of human UC, including weight loss, diarrhea, bloody stools, and colonic inflammation. This model provides a robust platform for preclinical efficacy testing of novel IBD therapeutics.

Pruritus (itch) is an unpleasant sensation that provokes the desire to scratch, ranging from mild annoyance to intractable, disabling conditions. It can be associated with primary skin disorders (atopic dermatitis, psoriasis) or systemic diseases (renal, cholestatic, hematologic, endocrine). HKeyBio offers two well-validated NHP pruritus models: mechanical damage induced model (mimicking wound healing-associated itch) and IL-31 induced model (directly activating the key immune-neural itching pathway). Both models recapitulate human chronic itch features, providing robust platforms for preclinical efficacy testing of novel anti-pruritic therapeutics.

Hidradenitis suppurativa (HS) is a chronic, painful, and disfiguring inflammatory skin disease affecting apocrine gland-bearing areas (axillae, inguinal regions, buttocks, chest). Its pathogenesis involves complex immune dysregulation, including innate immune responses (macrophages, neutrophils, IL-1β, TNF-α), Th1/Th17 cellular immunity, and B-cell involvement. HKeyBio offers a well-characterized NHP HS model that recapitulates key human HS features, including dermal tunnels, neutrophilic infiltration, and upregulation of HS-related inflammatory genes. This model provides a robust platform for preclinical efficacy testing of novel HS therapeutics.

SLE is a complex autoimmune disease characterized by autoantibody production, immune complex deposition, and multi‑organ damage (skin, joints, kidneys). HKeyBio offers a well‑characterized TLR‑7 agonist induced NHP SLE model that recapitulates key human features: elevated anti‑dsDNA, IFN‑α signature, and kidney pathology. This model provides a robust platform for efficacy testing of novel immunomodulators and supports IND‑enabling studies with comprehensive data packages.